New hope for aggressive lymphoma: targeted combo shows promise in early trial
NCT ID NCT04980222
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called glofitamab added to standard chemotherapy (R-CHOP) for people with a fast-growing type of lymphoma that has a high risk of coming back. The goal is to see if the combination is safe and helps more patients achieve complete remission. About 46 adults with untreated diffuse large B-cell lymphoma will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aarhus Universitetshospital Skejby
Aarhus N, 8200, Denmark
-
Baylor University Medical Center
Dallas, Texas, 75204, United States
-
Centre Henri Becquerel
Rouen, 76038, France
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Hopital Henri Mondor
Créteil, 94010, France
-
Hospital Clinic i Provincial de Barcelona
Barcelona, 08036, Spain
-
Hospital Clinico Universitario de Salamanca
Salamanca, 37007, Spain
-
Hospital General Universitario Gregorio Marañon
Madrid, 28007, Spain
-
Hospital Univ. 12 de Octubre; Servicio de Hematologia
Madrid, 28041, Spain
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center at Westchester
Harrison, New York, 10604, United States
-
Stanford Cancer Center
Stanford, California, 94305-5820, United States
-
Universitair Medisch Centrum Groningen
Groningen, 9713 GZ, Netherlands
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
Uniwersytecki Szpital Kliniczny; Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku
Wroclaw, 50-367, Poland
-
Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii
Gdansk, 80-211, Poland
-
Washington University; Wash Uni. Sch. Of Med
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can engineered immune cells tackle brain lymphoma?